Iovance Biotherapeutics financials at a glance

+ Portfolio

The revenue of Iovance Biotherapeutics is reported as 0.00119 billion Dollars in the fiscal year 2023. The earnings were -1.89 Dollars per share in 2023, which was 24.1 higher than 2022. And about -0.38411 billion Dollars are reported as free cash flow in the financials of Iovance Biotherapeutics 2023. No dividends were paid to the shareholders of the Iovance Biotherapeutics stock NasdaqGM:IOVA in the financial year 2023.

$1.19M

Revenue

$-1.89

Earnings Per Share

0.00%

Gross Margin %

$-,372.00M

Free Cash Flow

Revenue

1.19

Earnings Per Share

-1.89

Gross Margin %

0.00

Free Cash Flow

-,372.00

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Rev.	Revenue	N/A	$1.19M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-2.04	$-1.89	$-2.49	$-2.23	$-1.88	$-1.59	$-1.27	$-1.23	$-0.62	$-0.62	$-0.48	$-3.47
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0	0	0	0	0	0	0	0
Sha.	Shares	N/AM	279.31M	224.24M	157.17M	146.98M	126.5M	123.42M	89.45M	62.31M	48.57M	44.08M	22.06M
OCF	Operating Cash Flow	N/A	$-,361.82M	$-,292.76M	$-,227.94M	$-,205.13M	$-,158.89M	$0.00M	$-78.71M	$-32.67M	$-18.38M	$-8.63M	$0.00M
FCF	Free Cash Flow	N/A	$-,372.00M	$-,313.18M	$-,265.52M	$-,251.93M	$-,165.81M	$-,102.45M	$-91.72M	$-34.19M	$-19.52M	$-10.23M	$0.00M
FCFS	Free Cash Flow Per Share	$-1.78	$-1.63	$-1.97	$-1.73	$-1.82	$-1.33	$-1.05	$-1.22	$-0.62	$-0.44	$-0.41	$-0.38

Iovance Biotherapeutics financials at a glance

Financials

Discover